CC-13097

CC-13097 is a small molecule phosphodiesterase 4 (PDE4) inhibitor developed by Celgene (now Bristol Myers Squibb). It belongs to the phthalimide class of compounds and is the racemic form of the approved drug apremilast (Otezla). CC-13097 works by inhibiting the PDE4 enzyme, which is responsible for the degradation of cyclic adenosine monophosphate (cAMP) in inflammatory cells. By increasing intracellular cAMP levels, CC-13097 suppresses the production of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha), interleukin-12 (IL-12), and interleukin-23 (IL-23), while simultaneously promoting the production of anti-inflammatory mediators like interleukin-10 (IL-10). Although it demonstrated potent anti-inflammatory activity in preclinical and early clinical models of psoriasis and rheumatoid arthritis, its development was ultimately discontinued in favor of its pure S-enantiomer, apremilast, which exhibited a more favorable pharmacological profile.

Other names

rac-Apremilast